These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8869842)

  • 1. Antibiotic usage: pharmacoeconomic impact in a changing healthcare system.
    Milkovich G
    Drugs; 1996; 52 Suppl 2():80-2. PubMed ID: 8869842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future pharmacoeconomic criteria for the treatment of infections.
    Milkovich G
    Int J Antimicrob Agents; 2009 Jul; 34 Suppl 1():S12-4. PubMed ID: 19560668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective.
    Wai AO; Frighetto L; Marra CA; Chan E; Jewesson PJ
    Pharmacoeconomics; 2000 Nov; 18(5):451-7. PubMed ID: 11151398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.
    Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J
    J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989.
    Coleman RW; Rodondi LC; Kaubisch S; Granzella NB; O'Hanley PD
    Am J Med; 1991 Apr; 90(4):439-44. PubMed ID: 1901446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness opportunities for new antibiotics.
    Hillman A
    Pharmacoeconomics; 1994; 5(Suppl 2):40-3. PubMed ID: 10147288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection.
    Quenzer RW; Pettit KG; Arnold RJ; Kaniecki DJ
    Am J Manag Care; 1997 Jul; 3(7):1027-36. PubMed ID: 10173367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic pharmacoeconomics: an attempt to find the real cost of hospital antibiotic prescribing.
    Kerr JR; Barr JG; Smyth ET; O'Hare J; Bell PM; Callender ME
    Ulster Med J; 1993 Apr; 62(1):50-7. PubMed ID: 8516976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical effectiveness and costs of antibiotics in respiratory infections].
    Jahnz-Rózyk K
    Pol Merkur Lekarski; 2011 May; 30(179):327-9. PubMed ID: 21675134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and cost-effectiveness of antibiotic monitoring at a Veterans Administration hospital.
    O'Hanley P; Rodondi L; Coleman R
    Chemotherapy; 1991; 37 Suppl 3():22-5. PubMed ID: 1909229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.
    Davis R; Bryson HM
    Pharmacoeconomics; 1994 Sep; 6(3):249-69. PubMed ID: 10155268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effective treatment of lower respiratory tract infections.
    Garrelts JC; Herrington AM
    Pharmacoeconomics; 1996 Jul; 10(1):36-58. PubMed ID: 10160469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic usage: policy, clinical and pharmacoeconomic outcomes.
    Carbon C
    Drugs; 1996; 52 Suppl 2():78-9. PubMed ID: 8869841
    [No Abstract]   [Full Text] [Related]  

  • 15. Modified guidelines impact on antibiotic use and costs: duration of treatment for pneumonia in a neurosurgical ICU is reduced.
    Meyer E; Buttler J; Schneider C; Strehl E; Schroeren-Boersch B; Gastmeier P; Ruden H; Zentner J; Daschner FD; Schwab F
    J Antimicrob Chemother; 2007 Jun; 59(6):1148-54. PubMed ID: 17434880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic policies. Economics and effectiveness from a UK perspective.
    Davey P
    Drugs; 1996; 52 Suppl 2():83-7. PubMed ID: 8869843
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-Continuum Tool Is Associated with Reduced Utilization and Cost for Frequent High-Need Users.
    Hardin L; Kilian A; Muller L; Callison K; Olgren M
    West J Emerg Med; 2017 Feb; 18(2):189-200. PubMed ID: 28210351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic management and early discharge from hospital: an economic analysis.
    Gray A; Dryden M; Charos A
    J Antimicrob Chemother; 2012 Sep; 67(9):2297-302. PubMed ID: 22623630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The choice of antimicrobial therapy by application of pharmacoeconomic principles in view of the most frequently isolated pathogens at the Clinic for Infectious Diseases of the Clinical Center of Vojvodina].
    Stefan-Mikić S; Sević S; Jovanović N; Cvjetković D; Aleksić-Dordević M
    Med Pregl; 2010; 63 Suppl 1():52-9. PubMed ID: 21438205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.